Table 1. Patient characteristics and use... | American Society of Hematology

Table 1.

Patient characteristics and use of tumor cells

Patient	Stage^*	Prior therapy	Patient treated with thalidomide	Isotype	Specimen^†	Plasma cells (%)^‡	Response to thalidomide^1-153
Patient	Stage^*	Prior therapy	Patient treated with thalidomide	Isotype	Specimen^†	Plasma cells (%)^‡	SCID-hu B	SCID-hu B+L
1	IIA	Yes	Yes^1-155	IgG κ	BM	21	102	ND
2	IIIA	Yes	Not available	IgG κ	BM	30	12	ND
3	IIIA	Yes	Yes	κ light chain	BM^1-154	38	97	ND
4	IIIA	Yes	No	IgG λ	BM	88	159	ND
5	IIIA	Yes	Yes	IgG κ + κ	BM#	56	82	ND
6	IIIA	Yes	Yes	IgG κ	BM	8	172	ND
7	IIIA	Yes	Yes	IgA κ + κ	BM	33	85	25
8	III	Yes	Yes	IgG λ	BM^1-154	90	118	115
9	IIIB	Yes	Yes	IgA λ + λ	BM	18	91	32
10	IIIA	No	Yes	IgG λ + λ	BM	20	96	42
11	IIIA	Yes	No	IgA κ + κ	PB^1-154	35	ND	0.4
12	IIIA	No	No	IgG κ	BM	29	ND	0.04
13	IIIA	Yes	Yes	IgM κ	BM	58	ND	56
14	IIIA	Yes	Yes	IgA κ + κ	BM	60	ND	0.001

Patient	Stage^*	Prior therapy	Patient treated with thalidomide	Isotype	Specimen^†	Plasma cells (%)^‡	Response to thalidomide^1-153
Patient	Stage^*	Prior therapy	Patient treated with thalidomide	Isotype	Specimen^†	Plasma cells (%)^‡	SCID-hu B	SCID-hu B+L
1	IIA	Yes	Yes^1-155	IgG κ	BM	21	102	ND
2	IIIA	Yes	Not available	IgG κ	BM	30	12	ND
3	IIIA	Yes	Yes	κ light chain	BM^1-154	38	97	ND
4	IIIA	Yes	No	IgG λ	BM	88	159	ND
5	IIIA	Yes	Yes	IgG κ + κ	BM#	56	82	ND
6	IIIA	Yes	Yes	IgG κ	BM	8	172	ND
7	IIIA	Yes	Yes	IgA κ + κ	BM	33	85	25
8	III	Yes	Yes	IgG λ	BM^1-154	90	118	115
9	IIIB	Yes	Yes	IgA λ + λ	BM	18	91	32
10	IIIA	No	Yes	IgG λ + λ	BM	20	96	42
11	IIIA	Yes	No	IgA κ + κ	PB^1-154	35	ND	0.4
12	IIIA	No	No	IgG κ	BM	29	ND	0.04
13	IIIA	Yes	Yes	IgM κ	BM	58	ND	56
14	IIIA	Yes	Yes	IgA κ + κ	BM	60	ND	0.001

BM indicates bone marrow; PB, peripheral blood; and ND, experiment not done.

Stage at the time of study, according to the Durie-Salmon staging system.

†

Specimen used for inoculation into SCID-hu hosts.

‡

Percent of plasma cells in inoculate, determined by CD38/CD45 flow cytometry.

F1-153

Numbers represent percent change of final hIg in thalidomide-treated host compared to CMC-treated control hosts injected with myeloma cells from the same patient.

F1-155

Patient has been treated with thalidomide before or after the current study.

F1-154

Patient had high numbers of circulating plasma cells (plasma cell leukemia).

#Originally diagnosed with primary plasma cell leukemia.

View Large

This Feature Is Available To Subscribers Only